Martyno Lab, MB - financials and debts

Company age: 5 y. 11 mo.

Update

Martyno Lab - Company finances

EUR
2020
From: 2020-10-09
To: 2020-12-31
2021
From: 2021-01-01
To: 2021-12-31
2022
From: 2022-01-31
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 8,612 46,282 39,040 39,135 59,675 59,369
Profit before tax 7,521 12,236 -5,502 4,860 26,224 7,892
Net profit 7,521 12,852 -5,502 4,617 24,811 7,357
Equity 7,527 19,148 13,645 18,262 43,073 50,430
Liabilities - - 774 1,037 1,903 998
Non-current assets 0 1,181 675 1,117 19,367 17,355
Current assets 8,618 18,806 13,744 18,182 25,609 34,073
Total assets 8,618 19,987 14,419 19,299 44,976 51,428
Taxes paid
STI taxes - - - 2,400 2,638 2,481
Financial indicators
Revenue change y/y - +437.4% -15.6% +0.2% +52.5% -0.5%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 87.3% 64.3% -38.2% 23.9% 55.2% 14.3%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 99.9% 67.1% -40.3% 25.3% 57.6% 14.6%
Profit margin Net profit margin. Shows the overall profitability of the company. 87.3% 27.8% -14.1% 11.8% 41.6% 12.4%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 87.3% 26.4% -14.1% 12.4% 43.9% 13.3%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. - - 0.1 0.1 0.0 0.0
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. - - - - - -

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Martyno Lab - Social security debts

The amount of overdue SODRA debt for the company Martyno Lab as of the last working day is: 481 €

From To Debt, €
2026-09-14 2026-09-15 481.22
2026-09-05 2026-09-13 337.71
2026-09-01 2026-09-02 337.71
2026-08-26 2026-08-31 257.23
2026-08-23 2026-08-23 257.23
2026-08-19 2026-08-19 257.23
2026-08-16 2026-08-17 257.23
2026-08-07 2026-08-14 257.23
2026-08-01 2026-08-06 177.50
2026-07-24 2026-07-31 97.02
2026-07-14 2026-07-23 577.63
2026-07-07 2026-07-13 497.90
2026-07-01 2026-07-06 532.50
2026-06-11 2026-06-30 452.02
2026-06-02 2026-06-10 355.00
2026-05-13 2026-06-01 274.52
2026-05-11 2026-05-12 177.50
2026-05-04 2026-05-10 80.48
2026-05-03 2026-05-03 257.98
2026-04-15 2026-04-30 177.50
2026-04-01 2026-04-14 80.48
2026-03-15 2026-03-31 97.02
2026-03-03 2026-03-14 93.25
2026-02-13 2026-03-02 12.77
2023-07-19 2023-07-31 1646.79

Martyno Lab - VMI tax arrears

As of 2026-09-02, the amount of overdue STI tax debt of the company Martyno Lab is: 173 €

From To Overdue, €
2026-08-12 2026-09-02 172.95
2026-07-16 2026-07-26 173.7
2026-07-02 2026-07-15 0.75
2026-06-18 2026-07-01 345.9
2026-02-18 2026-03-08 172.95
2026-01-13 2026-01-22 150.0
2025-12-15 2025-12-18 150.0
2025-11-14 2025-11-25 150.0
2025-10-15 2025-10-22 150.0
2025-09-16 2025-10-05 150.0
2025-08-19 2025-08-25 150.0
2025-07-16 2025-07-25 118.0

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Martyno Lab, MB (code 305638611) is a small partnership engaged in the manufacture of other medical and dental devices, instruments and supplies. In 2025, the latest financial year, the company generated revenue of €59.4K and net profit of €7.4K, which corresponds to a profit margin of 12.4%. Revenue was broadly stable year on year, with a slight decline of 0.5% from 2024, while the two-year comparison still shows solid growth of 51.7% versus 2023. Profitability was much higher in 2024, when net profit reached €24.8K on revenue of €59.7K, after €4.6K in 2023. The 2025 balance sheet remained very strong, with total assets of €51.4K, equity of €50.4K and liabilities of just €998. This leaves an equity ratio of 98.1% and a debt-to-equity ratio of 0.02. Return on equity was 14.6% and return on assets 14.3%, while asset turnover stood at 1.15x, indicating efficient use of the asset base.